TickerFacts.

Company research / IONS

Ionis Pharmaceuticals Inc (IONS)

Build a valuation ↗↓ Download CSV

SEC name IONIS PHARMACEUTICALS INC · CIK 0000874015 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated CA
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Ionis Pharmaceuticals Inc reported revenue of $943.71M. Revenue grew 33.8% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $874.09M.

Key ratios (year ended 2025-12-31)

-40.4%
Operating margin
-40.4%
Net margin
-78.0%
Return on year-end equity
33.8%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-19

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$874.09M$943.71M$705.14M$787.65M$587.37M$810.46M$729.26M$1.12B$599.67M$514.18M$372.78M
Cost of Revenue$16.02M$15.91M$11.21M$9.13M$14.12M$10.84M$11.95M$4.38M$1.82M$0$0
R&D Expensen/a$915.62M$901.53M$899.62Mn/a$638.20M$531.00M$461.50M$411.90M$372.50M$340.40M
Operating Income-$594.35M-$381.68M-$475.08M-$353.73M-$410.19M-$30.19M-$172.08M$365.88M-$61.37M$31.05M-$20.16M
Net Income-$565.17M-$381.39M-$453.90M-$366.29M-$269.72M-$28.60M-$444.26M$278.14M$273.74M$346.0K-$60.40M
EPS (Diluted)n/a-$2.38-$3.04-$2.56-$1.90-$0.20-$3.18$1.90$2.07$0.15-$0.50
Total Assets$2.99B$3.52B$3.00B$2.99B$2.53B$2.61B$2.39B$3.23B$2.67B$1.32B$912.47M
Total Liabilities$2.55B$3.03B$2.42B$2.60B$1.96B$1.84B$1.65B$1.55B$1.48B$957.49M$812.90M
Long-Term Debtn/a$1.81B$1.25B$1.31B$1.19Bn/an/an/an/an/an/a
Shareholders' Equity$439.74M$489.09M$588.35M$386.69M$572.89M$771.74M$743.28M$1.47B$1.05B$281.01M$99.56M
Cash & Equivalents$350.06M$372.26M$242.08M$399.27M$276.47M$869.19M$397.66M$683.29M$278.82M$129.63M$84.69M
Operating Cash Flow-$496.43M-$268.58M-$500.95M-$307.51M-$274.37M$30.80M$35.89M$345.63M$602.91M$174.15M-$112.11M
Capital Expenditures$64.41M$51.44M$45.28M$23.80M$15.72M$11.96M$35.12M$30.91M$13.61M$34.76M$7.11M
Free Cash Flow-$560.84M-$320.03M-$546.23M-$331.32M-$290.09M$18.84M$772.0K$314.72M$589.30M$139.38M-$119.21M
Share Repurchasesn/an/an/an/a$0$0$90.55M$34.40M$0$0n/a
Shares Outstanding165.64M163.30M157.91M144.34M142.06M141.21M140.37M140.34M137.93M124.98M121.64M
Weighted Average Diluted Sharesn/a160.01M149.51M143.19M141.85M141.02M139.61M153.16M134.06M126.10M120.93M
EPS (Basic)n/a-$2.38-$3.04-$2.56-$1.90-$0.20-$3.18$2.00$2.09$0.15-$0.50

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView